Literature DB >> 18974152

The chemokine receptor CX3CR1 is involved in the neural tropism and malignant behavior of pancreatic ductal adenocarcinoma.

Federica Marchesi1, Lorenzo Piemonti, Giuseppe Fedele, Annarita Destro, Massimo Roncalli, Luca Albarello, Claudio Doglioni, Achille Anselmo, Andrea Doni, Paolo Bianchi, Luigi Laghi, Alberto Malesci, Luigi Cervo, Marialuisa Malosio, Michele Reni, Alessandro Zerbi, Valerio Di Carlo, Alberto Mantovani, Paola Allavena.   

Abstract

Tumor perineural dissemination is a hallmark of human pancreatic ductal adenocarcinoma (PDAC) and represents a major source of local tumor recurrence after surgery. In this study, we provide in vitro and in vivo evidence that the chemokine receptor CX3CR1 may be involved in the neurotropism of PDAC cells to local peripheral nerves. Neoplastic cells from PDAC cell lines and surgical specimens express the chemokine receptor CX3CR1, absent in normal pancreatic ducts. Its unique ligand, the transmembrane chemokine CX3CL1, is expressed by neurons and nerve fibers. CX3CR1 + PDAC cell lines migrated in response to human recombinant CX3CL1 and specifically adhered to CX3CL1-expressing cells of neural origin via mechanisms involving activation of G proteins, beta1 integrins, and focal adhesion kinase. In vivo experiments with transplanted PDAC showed that only CX3CR1-transfected tumor cells infiltrated the local peripheral nerves. Immunohistochemistry of CX3CR1 in PDAC specimens revealed that 90% of the samples were positive with a heterogeneous pattern of expression. High receptor score was significantly associated with more prominent tumor perineural infiltration evaluated histologically (P = 0.026). Regression analyses (univariate and multivariate) showed that high CX3CR1 expression and perineural invasion were strongly associated with local and earlier tumor recurrence (P = 0.007). Collectively, this study shows that the CX3CR1 receptor may be involved in PDAC tumor neurotropism and is a relevant and independent risk factor to predict an early local tumor relapse in resected patients. Thus, the CX3CR1-CX3CL1 axis could represent a valuable therapeutic target to prevent tumor perineural dissemination in pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18974152     DOI: 10.1158/0008-5472.CAN-08-1810

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  55 in total

1.  Fractalkine receptor CX(3)CR1 is expressed in epithelial ovarian carcinoma cells and required for motility and adhesion to peritoneal mesothelial cells.

Authors:  Mijung Kim; Lisa Rooper; Jia Xie; Andre A Kajdacsy-Balla; Maria V Barbolina
Journal:  Mol Cancer Res       Date:  2011-11-07       Impact factor: 5.852

Review 2.  Perineural invasion and associated pain in pancreatic cancer.

Authors:  Aditi A Bapat; Galen Hostetter; Daniel D Von Hoff; Haiyong Han
Journal:  Nat Rev Cancer       Date:  2011-09-23       Impact factor: 60.716

Review 3.  How Schwann cells facilitate cancer progression in nerves.

Authors:  Sylvie Deborde; Richard J Wong
Journal:  Cell Mol Life Sci       Date:  2017-06-19       Impact factor: 9.261

4.  Midkine promotes perineural invasion in human pancreatic cancer.

Authors:  Jun Yao; Wen-Yao Li; Shuo-Guo Li; Xiao-Shan Feng; She-Gan Gao
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

5.  Preliminary study correlating CX3CL1/CX3CR1 expression with gastric carcinoma and gastric carcinoma perineural invasion.

Authors:  Cheng-Yu Lv; Tao Zhou; Wei Chen; Xin-Dao Yin; Jian-Hong Yao; Yi-Fan Zhang
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

Review 6.  Targeting the cancer-stroma interaction: a potential approach for pancreatic cancer treatment.

Authors:  Xuqi Li; Qingyong Ma; Qinhong Xu; Wanxing Duan; Jianjun Lei; Erxi Wu
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

7.  Perineural invasion in early-stage cervical cancer and its relevance following surgery.

Authors:  Yi Zhu; Guonan Zhang; Yan Yang; Ling Cui; Shijun Jia; Yu Shi; Shuiqin Song; Shiqiang Xu
Journal:  Oncol Lett       Date:  2018-02-26       Impact factor: 2.967

8.  Targeting chemokine pathways in esophageal adenocarcinoma.

Authors:  Makardhwaj S Shrivastava; Zulfiqar Hussain; Orsolya Giricz; Niraj Shenoy; Rahul Polineni; Anirban Maitra; Amit Verma
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

9.  Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer.

Authors:  Jin-Hyeok Hwang; Johannes Voortman; Elisa Giovannetti; Seth M Steinberg; Leticia G Leon; Yong-Tae Kim; Niccola Funel; Joo Kyung Park; Min A Kim; Gyeong Hoon Kang; Sun-Whe Kim; Marco Del Chiaro; Godefridus J Peters; Giuseppe Giaccone
Journal:  PLoS One       Date:  2010-05-14       Impact factor: 3.240

Review 10.  Process of hepatic metastasis from pancreatic cancer: biology with clinical significance.

Authors:  Haojun Shi; Ji Li; Deliang Fu
Journal:  J Cancer Res Clin Oncol       Date:  2015-08-07       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.